Press Releases – Sanaria

Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine

June 3, 2025 By Alexander Hoffman In News, Press Releases No Comments

Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria® PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.

A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria

February 12, 2025 By Alexander Hoffman In News, Press Releases No Comments

Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases.

First-of-its-kind vaccine expands malaria protection for pregnant women

August 14, 2024 By Alexander Hoffman In In The Media, News, Press Releases, Publications No Comments

On August 14th, 2024, The Lancet Infectious Diseases released a publication entitled: "Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials."

Novel vaccine, PfSPZ-LARC2 Vaccine, to prevent malaria infection developed by Seattle Children’s Research Institute and Sanaria ready for human testing

April 1, 2024 By Alexander Hoffman In In The Media, News, Press Releases No Comments

In a report published on March 21, 2024 in EMBO Molecular Medicine (A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion) investigators at Seattle Children’s Research Institute and Sanaria Inc. describe the development of a whole malaria parasite vaccine strain that infects the liver, develops to the late liver stage, and then gets completely stuck and cannot burst out of the liver to cause symptomatic blood infection.

Sanaria Inc. Receives Major Funding for Malaria (PfSPZ) Repository

November 27, 2023 By Alexander Hoffman In News, Press Releases No Comments

Sanaria receives $1.5M from the Gates Foundation to make PfSPZ Challenge more accessible for future controlled human malaria infections (CHMIs) in the form of a repository.

INFECTIOUS MALARIA SPOROZOITES PRODUCED WITHOUT MOSQUITOES PROVIDE GROUND-BREAKING PROGRESS FOR MALARIA VACCINES AND BIOLOGY RESEARCH

December 7, 2022 By Alexander Hoffman In News, Press Releases No Comments

Scientists from Sanaria Inc., and collaborators at multiple institutions publish results in Nature reporting “In vitro production of infectious Plasmodium falciparum sporozoites.”

COLLABORATORS PUBLISH ARTICLE IN NATURE COMMUNICATIONS: PLASMODIUM FALCIPARUM 7G8 CHALLENGE PROVIDES CONSERVATIVE PREDICTION OF EFFICACY OF PFNF54-BASED PFSPZ VACCINE IN AFRICA

July 26, 2022 By Alexander Hoffman In News, Press Releases No Comments

ROCKVILLE, MD, USA – July 12, 2022 – Sanaria Inc., University of Maryland School of Medicine, Naval Medical Research Center, National Institutes of Health (USA), University of Bamako Malaria Research and Training Center (Mali), and University of Tübingen (Germany) published results in Nature Communications showing Plasmodium falciparum 7G8 human challenge trials provide a conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa.

Sanaria Announces the Start of Clinical Trials of its PfSPZ Vaccines in Mali and Indonesia

June 21, 2022 By Alexander Hoffman In News, Press Releases No Comments

Sanaria Inc. announces that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

SANARIA INC. AND SEATTLE CHILDREN’S RESEARCH INSTITUTE ANNOUNCE COLLABORATION FOR DEVELOPMENT OF GENETICALLY ATTENUATED MALARIA VACCINES

October 19, 2021 By Alexander Hoffman In Press Releases No Comments

Sanaria Inc. and Seattle Children’s Research Institute are proud to announce the signing of an agreement to collaborate on the development and commercialization of next generation PfSPZ vaccines attenuated by genetic engineering.

SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES

June 30, 2021 By Alexander Hoffman In Press Releases No Comments

In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.

Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine

June 8, 2021 By Alexander Hoffman In Press Releases No Comments

Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine. Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults.

EU Malaria Fund: Sanaria to receive financing to develop Malaria vaccine

November 5, 2020 By Alexander Hoffman In Press Releases No Comments

Sanaria to receive €12.9M for the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine from the EU Malaria Fund.

USPTO Awards Sanaria with the 2020 Patents for Humanity Award

August 27, 2020 By Alexander Hoffman In Awards, In The Media, News, Press Releases No Comments

USPTO awards Sanaria with the 2020 Patents for Humanity Award for Sanaria's malaria vaccine.

The Government of Equatorial Guinea, US Energy Companies, and Sanaria Sign Agreements to Extend Support for Clinical Development of PfSPZ Vaccine for Malaria and a Pathway Towards Malaria Elimination on Bioko Island

April 10, 2019 By Matt Feldman In News, Press Releases 1 Comment

Sanaria Inc. and the Government of Equatorial Guinea last week signed an agreement that continues their joint commitment to develop Sanaria® PfSPZ Vaccine as a tool for malaria elimination. This follows a new, broader agreement between the Government of Equatorial Guinea (EG) and industry partners, Marathon Oil Corporation, Noble Energy Inc. and Atlantic Methanol Production Company (AMPCO), to sponsor clinical development of Sanaria® PfSPZ Vaccine, including the Phase 3 clinical program starting in 2020. This long standing, successful partnership highlights the unique involvement of an African government and private-sector energy companies in developing a vaccine for a largely African problem.

Sanaria’s malaria vaccines clinical and manufacturing progress highlighted at International meetings in Baltimore

November 8, 2017 By Matt Feldman In News, Press Releases No Comments

Building upon publication of clinical trial results in Nature, PNAS, Lancet Infectious Diseases, and JCI Insight in 2017, Sanaria Inc. is highlighting the work of its many collaborators at a symposium entitled “Moving Toward a PfSPZ Malaria Vaccine for Protecting Travelers and Use in Elimination Campaigns” (session 133) at the 66th meeting of the American Society of Tropical Medicine and Hygiene in Baltimore, and then at the second 2017 International PfSPZ Consortium meeting held at the University of Maryland School of Medicine.

Sanaria’s PfSPZ Vaccine Achieves Durable Protection Against Heterologous Malaria Infection in a Clinical Trial

February 20, 2017 By Matt Feldman In Press Releases, Publications No Comments

In a report published today in the Proceedings of the National Academy of Sciences, investigators from the National Institute of Allergy and Infectious Diseases (NIAID), NIH and the University of Maryland School of Medicine reported that nine of fourteen subjects (64%) immunized with three doses of Sanaria® PfSPZ Vaccine were protected against homologous challenge with Plasmodium falciparum malaria 19 weeks after their last vaccine dose. Moreover, five of six of the protected subjects who underwent a subsequent heterologous challenge with Plasmodium falciparum 33 weeks after their last vaccine dose were protected.

Sanaria’s PfSPZ Vaccine Confers Significant Protection Against Natural Malaria infections in Mali

February 15, 2017 By Matt Feldman In Press Releases, Publications No Comments

In a report published today in The Lancet Infectious Diseases, investigators reported that Sanaria® PfSPZ Vaccine protected against natural infections of Plasmodium falciparum, the leading cause of malaria deaths and that protection was sustained for the 24 weeks of the study in an area of intense malaria transmission.

Sanaria’s PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial

February 15, 2017 By Matt Feldman In Press Releases, Publications No Comments

In a report published today in Nature, investigators from the University of Tübingen reported all nine subjects (100%) immunized with three doses of Sanaria® PfSPZ-CVac malaria vaccine in a recently completed clinical trial were protected against Plasmodium falciparum malaria when exposed to the disease 10 weeks after last vaccine dose. Professor Peter Kremsner, MD, Director of the Institute of Tropical Medicine at the University, led the clinical team.

Sanaria’s PfSPZ Vaccine Provides High-Level Defense Against Malaria In U.S. Navy and Army Clinical Investigation

January 12, 2017 By Matt Feldman In Press Releases No Comments

Sanaria Inc. continues to achieve success in its coordinated efforts to develop a safe, effective and affordable vaccine that delivers mass malaria protection in humans and promotes elimination of the disease worldwide. Research published today in JCI Insight by a team of clinical investigators at the Naval Medical Research Center and Walter Reed Army Institute of Research reports that Sanaria® PfSPZ Vaccine protected against Plasmodium falciparum malaria when clinical trial participants were exposed to two strains of parasites.

Sanaria® PfSPZ Vaccine Against Malaria Receives FDA Fast Track Designation

September 22, 2016 By Matt Feldman In Press Releases No Comments

Sanaria Inc. today announced it has received U.S. Food and Drug Administration (FDA) Fast Track designation for its preventative vaccine for malaria, Sanaria® PfSPZ Vaccine. Sanaria believes its PfSPZ Vaccine is the only malaria vaccine to have ever received this distinction.

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: